Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 15/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.61 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.61 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.61 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.61 |
| ▸ | HTR1B | P28222 | 2/20 | 0.61 |
| ▸ | HRH1 | P35367 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.60 |
| ▸ | HTR1A | P08908 | 2/20 | 0.59 |
| ▸ | DRD5 | P21918 | 2/20 | 0.59 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.59 |
| ▸ | DRD3 | P35462 | 2/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | PDE2A | O00408 | 1/20 | 0.59 |
| ▸ | PDE5A | O76074 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | INSR | P06213 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3762664 | 0.86 | P2RY14 (0.53) | P2RY14CYP3A4KCNH2TMEM97ADRB3 | |
| SCHEMBL13057701 | 0.79 | P2RY14 (0.48) | P2RY14CYP3A4KCNH2TMEM97ADRB3 | |
| SCHEMBL3757976 | 0.79 | P2RY14 (0.62) | P2RY14CYP3A4KCNH2TMEM97ADRB3 | |
| SCHEMBL2930702 | 0.79 | P2RY14 (0.62) | P2RY14CYP3A4KCNH2TMEM97ADRB3 | |
| SCHEMBL3752857 | 0.79 | P2RY14 (0.62) | P2RY14CYP3A4KCNH2TMEM97ADRB3 | |
| SCHEMBL3761498 | 0.78 | P2RY14 (0.61) | P2RY14CYP3A4KCNH2TMEM97ADRB3 | |
| SCHEMBL23796139 | 0.77 | NPSR1 (0.46) | P2RY14CYP3A4KCNH2TMEM97ADRB3 | |
| SCHEMBL30290138 | 0.77 | NPSR1 (0.46) | P2RY14CYP3A4KCNH2TMEM97ADRB3 | |
| SCHEMBL21247940 | 0.77 | P2RY14 (1.00) | P2RY14CYP3A4KCNH2TMEM97ADRB3 | |
| SCHEMBL30608305 | 0.76 | P2RY14 (1.00) | P2RY14KCNH2TMEM97ADRB3ADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298347-A1 | SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY | MERCK FROSST CANADA LTD (CA) | 2010-11-25 | — | — | US | disclosed |
| US-20100298347-A1 | SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY | MERCK FROSST CANADA LTD (CA) | 2010-11-25 | — | — | US | disclosed |
| US-20100298347-A1 | SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY | MERCK FROSST CANADA LTD (CA) | 2010-11-25 | — | — | US | disclosed |
| EP-2229373-A1 | SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY | Merck Frosst Canada Ltd. (CA) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009070873-A1 | SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY | MERCK FROSST CANADA LTD. (CA) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009070873-A1 | SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY | MERCK FROSST CANADA LTD. (CA) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298347-A1 | SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY | GPR119, GPR52, GPR35 | P2RY14 423/4885CYP3A4 3691/4885KCNH2 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.